Chimerix Q3 2023 Earnings Report $3.55 -0.11 (-3.01%) As of 01/17/2025 04:00 PM Eastern Earnings HistoryForecast Chimerix EPS ResultsActual EPS-$0.27Consensus EPS -$0.22Beat/MissMissed by -$0.05One Year Ago EPSN/AChimerix Revenue ResultsActual Revenue$0.01 millionExpected Revenue$0.22 millionBeat/MissMissed by -$210.00 thousandYoY Revenue GrowthN/AChimerix Announcement DetailsQuarterQ3 2023Date11/2/2023TimeN/AConference Call ResourcesPress ReleaseCMRX Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Powered by Chimerix Earnings HeadlinesChimerix to Speak Today at The White House Cancer Moonshot ForumJanuary 13, 2025 | markets.businessinsider.comChimerix Receives ‘Buy’ Rating from Edward White on Promising Drug Development and Strong Financial OutlookDecember 30, 2024 | markets.businessinsider.comGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which is why I'm recommending ONE coin to all investors right now. January 18, 2025 | Crypto 101 Media (Ad)A Glimpse Into The Expert Outlook On Chimerix Through 4 AnalystsDecember 30, 2024 | benzinga.comPromising Outlook for Chimerix: Strategic Developments and Financial Strength Justify Buy RatingDecember 30, 2024 | markets.businessinsider.comChimerix Submits Dordaviprone New Drug Application for Accelerated Approval to U.S. FDA for Patients with Recurrent H3 K27M-Mutant Diffuse GliomaDecember 30, 2024 | globenewswire.comSee More Chimerix Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Chimerix? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Chimerix and other key companies, straight to your email. Email Address About ChimerixChimerix (NASDAQ:CMRX), a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors. The company also develops ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for oncology indications; and CMX521, a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2. It has license agreement with SymBio Pharmaceuticals to develop and commercialize TEMBEXA for human diseases other than orthopoxviruses, including smallpox. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.View Chimerix ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Why Amazon’s Next Earnings Could Trigger a Stock BreakoutS&P 500 Earnings Set to Shine: January's Critical Market TestCiena Rebounds: AI and Strong Guidance Drive Post-Earnings SurgeHistory Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead? Upcoming Earnings Interactive Brokers Group (1/21/2025)Netflix (1/21/2025)Capital One Financial (1/21/2025)HDFC Bank (1/21/2025)3M (1/21/2025)Prologis (1/21/2025)Charles Schwab (1/21/2025)Abbott Laboratories (1/22/2025)Amphenol (1/22/2025)GE Vernova (1/22/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
